Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* For MAIN period (GHLIQUID-1516):~* Born small for gestational age (SGA) with birth weight and birth length below the 10th percentile for gestational age, and additional either birth length below or equal to -2.0 standard deviation score (SDS) or birth weight below or equal to -2.0 SDS for gestational age~* Growth failure with height at -2.0 SDS or below for chronological age (CA)~* Normal growth hormone (GH) production, defined as peak GH level \> 10 ng/mL in one GH provocation test~* For EXTENSION period (GHLIQUID-1517):~* Subjects who completed the main period~* Chronological age (CA) for boys at least 4 years, but maximum 11 years~* Chronological age (CA) for girls at least 4 years, but maximum 10 years~Exclusion Criteria:~* Subjects with diabetes mellitus~* Subjects suffering from malignancy~* Several medical conditions

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- 0.033 mg / NN-220 (Type: EXPERIMENTAL): In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
- 0.067 mg / NN-220 (Type: EXPERIMENTAL): In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
- No treatment (Type: NO_INTERVENTION): No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
- No treatment --> 0.033 mg (Type: EXPERIMENTAL): In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
- No treatment --> 0.067 mg (Type: EXPERIMENTAL): In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period

Based on this trial design, predict the completion outcome and termination type (if applicable).